Ku EJ, Lee DH, Jeon HJ, et al. - Treatment of type 2 diabetes (T2D) using quadruple combination therapy with either empagliflozin or dapagliflozin results in a positive long-term impact in the glycemic control and body weight reduction with generally good tolerance. Use of empagliflozin outperforms dapagliflozin use, in general.

• This is a 3-year open-label, prospective observational study of 362 patients with T2D who were given empagliflozin (25mg/day, n=185) or dapagliflozin (10mg/day, n=177) in addition to the existing triple drug regimen.

• Alterations in HbA1c and fasting plasma glucose in the empagliflozin and dapagliflozin group were -1.7% and -60.0 mg/dL, and -1.1% and -48.1 mg/dL, respectively, at 3 years.

• With empagliflozin use, a significantly greater bodyweight reduction (-4.5 kg vs -1.0 kg) was achieved and HDL cholesterol and LDL cholesterol were beneficially impacted.

• No difference in the overall incidence of adverse events and cardiovascular events and mortality was found between the two groups.